Gliclazide tablets are second-generation sulfonylurea hypoglycemic agents, which are insulinotropic agents. By binding to sulfonylurea receptors on pancreatic beta cells, they stimulate pancreatic beta cells to secrete insulin, thereby achieving blood glucose control. Gliclazide is also able to reduce platelet aggregation and blood viscosity. Therefore, Gliclazide is mainly indicated in type II diabetes with surviving pancreatic beta cell function, and cannot be used in type I diabetes or gestational diabetes. Gliclazide extended-release tablets should be taken within 5-10 minutes before meals, and the dose and frequency of dosing are related to the level of blood glucose; the dose of the drug should be adjusted regularly according to the blood glucose situation, and attention should be paid to regular diet and regular blood glucose monitoring during the dosing period to avoid serious hypoglycemia.